Table 3.
Association between gene polymorphisms on overall survival of osteosarcoma patients
| Gene | Patients | % | Deaths | % | Adjusted HR (95% CI)1 | P values | |
|---|---|---|---|---|---|---|---|
| ERCC1 rs11615 | CC | 116 | 67.44 | 22 | 53.66 | 1.0 | - |
| CT | 31 | 18.02 | 8 | 19.51 | 1.49 (0.50-4.03) | 0.4 | |
| TT | 25 | 14.53 | 11 | 26.83 | 3.36 (1.19-9.16) | 0.07 | |
| ERCC1 rs2298881 | AA | 66 | 38.37 | 11 | 26.83 | 1.0 | - |
| AC | 82 | 47.67 | 20 | 48.78 | 1.61 (0.66-4.07) | 0.25 | |
| CC | 24 | 13.95 | 10 | 24.39 | 3.57 (1.10-11.35) | 0.01 | |
| ERCC2 rs13181 | AA | 143 | 83.14 | 33 | 80.49 | 1.0 | - |
| AC | 18 | 10.47 | 5 | 12.20 | 1.28 (0.33-4.19) | 0.66 | |
| CC | 11 | 6.40 | 3 | 7.32 | 1.25 (0.20-5.60) | 0.75 | |
| ERCC2 rs1799793 | GG | 121 | 70.35 | 27 | 65.85 | 1.0 | - |
| GA | 30 | 17.44 | 8 | 19.51 | 1.27 (0.44-3.38) | 0.61 | |
| AA | 21 | 12.21 | 6 | 14.63 | 1.39 (0.40-4.26) | 0.53 | |
| ERCC4 rs1800067 | GG | 162 | 94.19 | 38 | 92.68 | 1.0 | - |
| GA | 7 | 4.07 | 2 | 4.88 | 1.31 (0.12-8.36) | 0.76 | |
| AA | 3 | 1.74 | 1 | 2.44 | 1.63 (0.03-32.04) | 0.69 | |
| ERCC5 rs1047768 | TT | 65 | 37.79 | 14 | 34.15 | 1.0 | - |
| TC | 73 | 42.44 | 18 | 43.90 | 1.19 (0.50-2.88) | 0.67 | |
| CC | 34 | 19.77 | 9 | 21.95 | 1.31 (0.44-3.79) | 0.58 | |
| XPA rs1800975 | GG | 71 | 41.28 | 16 | 39.02 | 1.0 | - |
| GA | 77 | 44.77 | 19 | 46.34 | 1.13 (0.49-2.60) | 0.76 | |
| AA | 24 | 13.95 | 6 | 14.63 | 1.15 (0.32-3.70) | 0.8 | |
| XPC rs2228000 | CC | 81 | 47.09 | 18 | 43.90 | 1.0 | - |
| CT | 71 | 41.28 | 18 | 43.90 | 1.19 (0.52-2.69) | 0.65 | |
| TT | 20 | 11.63 | 5 | 12.20 | 1.17 (0.29-4.00) | 0.79 | |
| XPC rs2228001 | AA | 67 | 38.95 | 15 | 36.59 | 1.0 | - |
| AC | 81 | 47.09 | 20 | 48.78 | 1.14 (0.50-2.65) | 0.74 | |
| CC | 24 | 13.95 | 7 | 17.07 | 1.43 (0.42-4.51) | 0.51 |
1
Adjusted for age, gender, tumor stage, type of therapy, tumor location and metastasis.